Amphastar Pharmaceuticals AMPH Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's deferred tax assets?
- Amphastar Pharmaceuticals (AMPH) reported deferred tax assets of $42.46M in Q1 2026.
- How has Amphastar Pharmaceuticals's deferred tax assets changed year-over-year?
- Amphastar Pharmaceuticals's deferred tax assets decreased by 40.3% year-over-year, from $71.12M to $42.46M.
- What is the long-term trend for Amphastar Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's deferred tax assets has grown at a 11.2% compound annual growth rate (CAGR), from $24.98M to $42.46M.
- What does deferred tax assets mean?
- Represents future tax benefits arising from temporary differences between the book value of assets/liabilities and their tax basis, or from carry-forward tax losses. These assets are realized when the firm generates sufficient taxable income to offset these differences. It serves as an indicator of future tax savings potential.